Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1995 5
1996 11
1997 5
1998 5
1999 1
2000 6
2001 5
2002 7
2003 6
2004 6
2005 8
2006 8
2007 17
2008 14
2009 8
2010 13
2011 5
2012 5
2013 5
2014 6
2015 3
2016 1
2017 2
2018 1
2019 1
2020 2
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. Among authors: rixe o. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Free article. Clinical Trial.
Axitinib (AG-013736).
Kelly RJ, Rixe O. Kelly RJ, et al. Among authors: rixe o. Recent Results Cancer Res. 2010;184:33-44. doi: 10.1007/978-3-642-01222-8_3. Recent Results Cancer Res. 2010. PMID: 20072829 Review.
Metastatic melanoma: chemotherapy.
Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D. Bajetta E, et al. Among authors: rixe o. Semin Oncol. 2002 Oct;29(5):427-45. doi: 10.1053/sonc.2002.35238. Semin Oncol. 2002. PMID: 12407508 Review.
Sunitinib malate.
Izzedine H, Buhaescu I, Rixe O, Deray G. Izzedine H, et al. Among authors: rixe o. Cancer Chemother Pharmacol. 2007 Aug;60(3):357-64. doi: 10.1007/s00280-006-0376-5. Epub 2006 Nov 30. Cancer Chemother Pharmacol. 2007. PMID: 17136543
Metastatic malignant melanoma.
Meric JB, Rixe O, Khayat D. Meric JB, et al. Among authors: rixe o. Drugs Today (Barc). 2003;39 Suppl C:17-38. Drugs Today (Barc). 2003. PMID: 14988744 Review.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Coveler AL, et al. Among authors: rixe o. J Immunother Cancer. 2023 Jun;11(6):e005584. doi: 10.1136/jitc-2022-005584. J Immunother Cancer. 2023. PMID: 37385724 Free PMC article. Clinical Trial.
Renal toxicity of targeted therapies.
Kelly RJ, Billemont B, Rixe O. Kelly RJ, et al. Among authors: rixe o. Target Oncol. 2009 Apr;4(2):121-33. doi: 10.1007/s11523-009-0109-x. Epub 2009 May 6. Target Oncol. 2009. PMID: 19421832 Review.
[Telomeres, telomerase and cancer].
Soria JC, Rixe O. Soria JC, et al. Among authors: rixe o. Bull Cancer. 1997 Oct;84(10):963-70. Bull Cancer. 1997. PMID: 9435798 Free article. Review. French.
Gemcitabine-induced thrombotic microangiopathy: a systematic review.
Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S, Casimir N, Billemont B, Deray G. Izzedine H, et al. Among authors: rixe o. Nephrol Dial Transplant. 2006 Nov;21(11):3038-45. doi: 10.1093/ndt/gfl507. Epub 2006 Sep 12. Nephrol Dial Transplant. 2006. PMID: 16968717 Review. No abstract available.
151 results